Tarsus Pharmaceuticals (TARS) Loses -15.59% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Tarsus Pharmaceuticals, Inc. (TARS) has been beaten down lately with too much selling pressure. While the stock has lost 15.6% over the past four weeks, there is light at the end of the tunnel as it is now in oversold territory and Wall Street analysts expect the company to report better earnings than they predicted earlier.
We use Relative Strength Index (RSI), one of the most commonly used technical indicators, for spotting whether a stock is oversold. This is a momentum oscillator that measures the speed and change of price movements.
RSI oscillates between zero and 100. Usually, a stock is considered oversold when its RSI reading falls below 30.
Technically, every stock oscillates between being overbought and oversold irrespective of the quality of their fundamentals. And the beauty of RSI is that it helps you quickly and easily check if a stock's price is reaching a point of reversal.
So, by this measure, if a stock has gotten too far below its fair value just because of unwarranted selling pressure, investors may start looking for entry opportunities in the stock for benefitting from the inevitable rebound.
However, like every investing tool, RSI has its limitations, and should not be used alone for making an investment decision.
The RSI reading of 29.83 for TARS is an indication that the heavy selling could be in the process of exhausting itself, so the stock could bounce back in a quest for reaching the old equilibrium of supply and demand.
This technical indicator is not the only factor that calls for a potential rebound for the stock. There is a fundamental indicator as well. A strong agreement among sell-side analysts covering TARS in raising earnings estimates for the current year has led to an increase in the consensus EPS estimate by 19.5% over the last 30 days. And an upward trend in earnings estimate revisions usually translates into price appreciation in the near term.
Moreover, TARS currently has a Zacks Rank #2 (Buy), which means it is in the top 20% of more than the 4,000 stocks that we rank based on trends in earnings estimate revisions and EPS surprises. This is a more conclusive indication of the stock's potential turnaround in the near term. You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Tarsus Pharmaceuticals, Inc. (TARS) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
39 minutes ago
- Yahoo
Guided Therapeutics Receives $700,000 Purchase Order and Initial Payment from New Chinese Distributor
PEACHTREE CORNERS, Ga., June 10, 2025--(BUSINESS WIRE)--Guided Therapeutics, Inc. (OTCQB: GTHP), the maker of the LuViva Advanced Cervical Scan, announced today that it had received a purchase order and first payment from Hangzhou Dongye Medical Technology Company Ltd (HDMT) for 35 LuViva systems. HDMT will order directly from Guided Therapeutics and the devices will be assembled and tested by Guided Therapeutics' Chinese partner, Shandong Yaohua Medical Instrument Corporation (SMI). HDMT is in Hangzhou City, Zhejiang Province, where it is the exclusive gynecology products provider for 42 hospitals that perform approximately two million cervical cancer screenings annually. Said Yang Dongye, CEO of HDMT: "We are extremely impressed with the performance of LuViva and our goal is to eventually replace the current screening tests with LuViva." The purchase order for $700,000 is to supply HDMT with 35 systems over the next eight months starting in July of this year. "We are extremely pleased to be working with HDMT to bring LuViva to Zhejiang Province and anticipate making initial shipments next month," added Mark Faupel, Guided Therapeutics' CEO. "Working directly with an exclusive provider of gynecology products that can potentially conduct two million LuViva tests each year is a major advance for GTI." About Guided Therapeutics Guided Therapeutics, Inc. (OTCQB: GTHP) is the maker of a rapid and painless testing platform based on its patented biophotonic technology that utilizes light for the early detection of disease at the cellular level. The Company's first product is the LuViva® Advanced Cervical Scan, a non-invasive device used to detect cervical disease instantly and at the point of care. In a multi-center clinical trial with women at risk for cervical disease, the technology was able to detect cervical cancer up to two years earlier than conventional modalities, according to published reports. For more information, visit: The Guided Therapeutics LuViva® Advanced Cervical Scan is an investigational device and is limited by federal law to investigational use in the U.S. LuViva, the wave logo and "Early detection, better outcomes" are registered trademarks owned by Guided Therapeutics, Inc. Forward-Looking Statements Disclaimer: A number of the matters and subject areas discussed in this news release that are not historical or current facts deal with potential future circumstances and developments. The discussion of such matters and subject areas is qualified by the inherent risks and uncertainties surrounding future expectations generally and also may materially differ from Guided Therapeutics' actual future experience involving any of or more of such matters and subject areas. Such risks and uncertainties include those related to the early stage of commercialization of products, the uncertainty of market acceptance of products, the uncertainty of development or effectiveness of distribution channels, the intense competition in the medical device industry, the sufficiency of capital raised in prior financings and the ability to realize their expected benefits, the uncertainty of future capital to develop products or continue as a going concern, the uncertainty of regulatory approval of products, and the dependence on licensed intellectual property, as well as those that are more fully described from time to time under the heading "Risk Factors" in Guided Therapeutics' reports filed with the SEC, including Guided Therapeutics' Annual Report on Form 10-K for the fiscal year ended December 31, 2024 and subsequent filings. View source version on Contacts Mark FaupelGuided Therapeutics770-242-8723
Yahoo
an hour ago
- Yahoo
Academy Sports and Outdoors, Inc. (ASO) Lags Q1 Earnings and Revenue Estimates
Academy Sports and Outdoors, Inc. (ASO) came out with quarterly earnings of $0.76 per share, missing the Zacks Consensus Estimate of $0.91 per share. This compares to earnings of $1.08 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of -16.48%. A quarter ago, it was expected that this company would post earnings of $1.82 per share when it actually produced earnings of $1.96, delivering a surprise of 7.69%. Over the last four quarters, the company has surpassed consensus EPS estimates just once. Academy Sports and Outdoors , which belongs to the Zacks Leisure and Recreation Products industry, posted revenues of $1.35 billion for the quarter ended April 2025, missing the Zacks Consensus Estimate by 1.37%. This compares to year-ago revenues of $1.36 billion. The company has topped consensus revenue estimates just once over the last four quarters. The sustainability of the stock's immediate price movement based on the recently-released numbers and future earnings expectations will mostly depend on management's commentary on the earnings call. Academy Sports and Outdoors shares have lost about 22.9% since the beginning of the year versus the S&P 500's gain of 2.1%. While Academy Sports and Outdoors has underperformed the market so far this year, the question that comes to investors' minds is: what's next for the stock? There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions. Investors can track such revisions by themselves or rely on a tried-and-tested rating tool like the Zacks Rank, which has an impressive track record of harnessing the power of earnings estimate revisions. Ahead of this earnings release, the estimate revisions trend for Academy Sports and Outdoors: unfavorable. While the magnitude and direction of estimate revisions could change following the company's just-released earnings report, the current status translates into a Zacks Rank #4 (Sell) for the stock. So, the shares are expected to underperform the market in the near future. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. It will be interesting to see how estimates for the coming quarters and current fiscal year change in the days ahead. The current consensus EPS estimate is $2.14 on $1.63 billion in revenues for the coming quarter and $6 on $6.15 billion in revenues for the current fiscal year. Investors should be mindful of the fact that the outlook for the industry can have a material impact on the performance of the stock as well. In terms of the Zacks Industry Rank, Leisure and Recreation Products is currently in the bottom 22% of the 250 plus Zacks industries. Our research shows that the top 50% of the Zacks-ranked industries outperform the bottom 50% by a factor of more than 2 to 1. LiveOne (LVO), another stock in the broader Zacks Consumer Discretionary sector, has yet to report results for the quarter ended March 2025. The results are expected to be released on June 18. This company is expected to post quarterly loss of $0.05 per share in its upcoming report, which represents a year-over-year change of -66.7%. The consensus EPS estimate for the quarter has remained unchanged over the last 30 days. LiveOne's revenues are expected to be $27.86 million, down 9.8% from the year-ago quarter. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Academy Sports and Outdoors, Inc. (ASO) : Free Stock Analysis Report LiveOne, Inc. (LVO) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Yahoo
an hour ago
- Yahoo
Buy This Tech Stock (ADBE) Down 40% for AI-Powered Upside
Adobe (ADBE) stock trades 40% below its all-time highs heading into its Q2 FY25 earnings release on Thursday. The creative software powerhouse, which has doubled the Tech sector over the past 15 years, tanked as Wall Street worries about slowing growth and valuation levels. Most importantly, investors need to know if Adobe can fend off the rapid acceleration of artificial intelligence offerings that enable users to generate high-end creative content from images to videos with the click of a button and almost no skills. Adobe is not going down without a fight, rolling out AI features throughout its portfolio. On top of that, the creative software giant has continued to improve its artificial intelligence-powered content creation service, Adobe Firefly, since it launched over two years ago. ADBE stock is holding ground at a key technical range and trading at a discount to Tech in terms of forward earnings. Now might be the time for investors to consider buying beaten-down Adobe on the dip for long-term upside. Adobe's revenue growth has slowed recently, averaging 11% sales expansion between FY22 and FY24. This came after the owner of Photoshop grew its sales by 15% to 25% for seven straight years after transitioning to a subscription model. The slower revenue growth forced Wall Street to recalibrate its valuation, especially in a higher interest rate environment. Adobe's earnings revisions also moved sideways over the past few years, though its actual earnings grew significantly. Image Source: Zacks Investment Research Wall Street was also disappointed that Adobe had to scrap its planned Figma acquisition over regulatory headwinds in late 2023. Adobe is still waiting for another opportunity to deploy its cash and diversify. Most critically, investors are worried that Adobe's creative software suite could become essentially obsolete because of AI. Multiple generative AI companies allow people to create intricate, high-quality images, videos, and beyond at lightning speed without any training, design skills, or technical expertise. Adobe's industry-leading creative software has been used by everyone from Hollywood movie studios and best-selling artists to college students and offices for years. ADBE's offerings include Photoshop, Premiere Pro, Illustrator, and Lightroom. On top of its core design-focused software, Adobe expanded its more traditional business-related segments beyond PDFs and e-signatures. Image Source: Zacks Investment Research Wall Street worries that even Hollywood studios and other giants will utilize AI more and more. Meanwhile, marketing companies, advertisers, and beyond are even more likely to turn to artificial intelligence for their creative content creation needs. Adobe has crucially rolled out artificial intelligence features into Photoshop and beyond to combat new-age AI-focused challengers. Most importantly, it unveiled its creative generative AI platform, Firefly, in 2023. It has gone all in on its Firefly AI platform since then. The company boasted in an April 24 press release that 'Adobe Firefly has revolutionized the creative industry and generated more than 22 billion assets worldwide' since its debut. The firm unveiled the latest release of Firefly at the end of April, which 'unifies AI-powered tools for image, video, audio, and vector generation into a single, cohesive platform and introduces many new capabilities.' Image Source: Zacks Investment Research 'Firefly has evolved into the ultimate creative AI solution, designed to be commercially safe from the ground up. Leading brands, including Deloitte, Tapestry, Paramount+, and Pepsi, have harnessed Firefly to streamline workflows and scale content production, resulting in faster time-to-market, better performing campaigns, and innovative, personalized experiences.' Adobe's generative AI features are designed to be commercially viable, while other services could run into a ton of copyright infringement issues and other legal battles. On top of that, Firefly for mobile 'will be able to generate amazing images and videos on the go, right from your iOS or Android device.' Adobe is projected to grow its revenue by 9% in FY25 and 10% in FY26 to reach $25.63 billion. ADBE's adjusted earnings are projected to jump by 11% and 13%, respectively. Image Source: Zacks Investment Research The company has beaten our bottom-line estimates for five years running. Its earnings estimates have held up since its Q1 FY25 release in early March after it reaffirmed its FY2025 financial targets, boosted by its ability to 'capitalize on the acceleration of the creative economy driven by AI.' Adobe stock has soared nearly 1,500% in the past 15 years to double the Tech sector. This huge outperformance includes a 2% climb in the past five years vs. Tech's 110%. ADBE is trading around where it was five years ago after holding its ground near its pre-Covid selloff highs. The tech stock is back above its very long-term 21-week moving average while trading at roughly neutral RSI levels. ADBE is trading 40% below its highs and 20% below its average Zacks price target. Plus, on the speculative side, Adobe (currently trading at $416 a share) could announce a stock split at some point to make it more appealing to retail investors and traders. Image Source: Zacks Investment Research The selloff, mixed with its solid earnings growth outlook, has it trading at a 75% discount to its all-time highs and 33% below its median at 23.5X forward 12-month earnings. Adobe is even trading at a 10% discount to the Tech sector despite its long-term outperformance. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Adobe Inc. (ADBE) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
